The European Medicines Agency (EMA) said on Thursday it had recommended the marketing for people over 12 of AstraZeneca’s preventive treatment Evusheld, intended for people who lack antibodies and whose bodies are resistant to vaccination. .
The European regulator “recommended granting marketing authorization for Evusheld, developed by AstraZeneca AB, for the prevention of Covid-19 in adults and adolescents from 12 years of age weighing at least 40 kg before potential exposureto the virus, the EMA said in a statement.
–
